Staffing Standards for Patient Populations Sample Clauses

Staffing Standards for Patient Populations. The Employer and Association agree that the assignment of patients will take into consideration staffing standards, patient conditions and departmental needs. o Medical/Surgical units (includes Medical, Post Surgery, Med Oncology and Tele units): 1 RN: 1:5 o Progressive Care units (includes ACC, CCU, Rainier PCU, CVSS, PCU): 1:4 o Critical Care (includes CVICU/MSICU/Neuro ICU): 1:1 or 1:2 o ED: 1:4 o OR: 1 RN Circulator; 1 Scrub; higher level cases may have a second RN o PACU: 1:2 o NICU: 1:2-3 o Birth Center: 1:1 or 1:2 o Women and Infant: 1:4 couplets o Antepartum: 1:3 stable or 1:1 non-stable • Standards for units not listed will be established by the Staffing Committee. • Unscheduled absences, including intermittent FMLA, are counted as a filled shift for purposes of the staffing standards. • RNs and LPNs who leave the floor for reasons including but not limited to transport, a code response, etc., shall be counted as a filled shift. • Remedy is limited to the shift on which the deviation occurred for the nurse whose assignment exceeds the staffing standards on the affected unit and shift. The remedy shall be in the form of an hourly premium paid for that specific shift and unit of $5.00 per hour. • Premium pay as described above is the exclusive remedy for deviations from these standards.
AutoNDA by SimpleDocs
Staffing Standards for Patient Populations. The Employer and Association agree that the assignment of patients will take into consideration staffing standards, patient conditions and departmental needs. o Medical/Surgical units (includes Medical, Post Surgery, Med Oncology and Tele units): 1 RN 1 LPN Team: 1:7, or 1 RN: 1:5 o Progressive Care units (includes ACC, CCU, Rainier PCU, CVSS, PCU): 1:4 o Critical Care (includes CVICU/MSICU/Neuro ICU): 1:1 or 1:2 o ED: 1:4 o OR: 1 RN Circulator; 1 Scrub; higher level cases may have a second RN o PACU: 1:2 o NICU: 1:2-3 o Birth Center: 1:1 or 1:2 o Women and Infant: 1:4 couplets o Antepartum: 1:3 stable or 1:1 non-stable • Standards for units not listed will be established by the Staffing Committee no later than July 1, 2017. • Unscheduled absences, including intermittent FMLA, are counted as a filled shift for purposes of the staffing standards. • RNs and LPNs who leave the floor for reasons including but not limited to transport, a code response, etc., shall be counted as a filled shift. • The Employer will implement the system no later than July 1, 2017. • Remedy is limited to the shift on which the deviation occurred for the nurse whose assignment exceeds the staffing standards on the affected unit and shift. The remedy shall be in the form of an hourly premium paid for that specific shift and unit of $5.00 per hour. • Premium pay as described above is the exclusive remedy for deviations from these standards.

Related to Staffing Standards for Patient Populations

  • Service Level Standards In addition to all other requirements in this Agreement, and in accordance with the Best Claims Practices & Estimating Guidelines, Vendor shall use reasonable and good faith efforts to meet the Service Level Standards set forth below.

  • Benchmarks for Measuring Accessibility For the purposes of this Agreement, the accessibility of online content and functionality will be measured according to the W3C’s Web Content Accessibility Guidelines (WCAG) 2.0 Level AA and the Web Accessibility Initiative Accessible Rich Internet Applications Suite (WAI-ARIA) 1.0 for web content, which are incorporated by reference.

  • Standards for Determining Commercial Reasonableness Borrower and Silicon agree that a sale or other disposition (collectively, "sale") of any Collateral which complies with the following standards will conclusively be deemed to be commercially reasonable: (i) Notice of the sale is given to Borrower at least seven days prior to the sale, and, in the case of a public sale, notice of the sale is published at least seven days before the sale in a newspaper of general circulation in the county where the sale is to be conducted; (ii) Notice of the sale describes the collateral in general, non-specific terms; (iii) The sale is conducted at a place designated by Silicon, with or without the Collateral being present; (iv) The sale commences at any time between 8:00 a.m. and 6:00 p.m; (v) Payment of the purchase price in cash or by cashier's check or wire transfer is required; (vi) With respect to any sale of any of the Collateral, Silicon may (but is not obligated to) direct any prospective purchaser to ascertain directly from Borrower any and all information concerning the same. Silicon shall be free to employ other methods of noticing and selling the Collateral, in its discretion, if they are commercially reasonable.

  • Quality Standards Each Party agrees that the nature and quality of its products and services supplied in connection with the other Party's Marks will conform to quality standards set by the other Party. Each Party agrees to supply the other Party, upon request, with a reasonable number of samples of any Materials publicly disseminated by such Party which utilize the other Party's Marks. Each Party will comply with all applicable laws, regulations, and customs and obtain any required government approvals pertaining to use of the other Party's marks.

  • Quality Assurance Program An employee shall be entitled to leave of absence without loss of earnings from her or his regularly scheduled working hours for the purpose of writing examinations required by the College of Nurses of Ontario arising out of the Quality Assurance Program.

  • Human and Financial Resources to Implement Safeguards Requirements The Borrower shall make available necessary budgetary and human resources to fully implement the EMP and the RP.

  • Safety Standards Performance of the Contract for all commodities or contractual services must comply with requirements of the Occupational Safety and Health Act and other applicable State of Florida and federal requirements.

  • Performance Standards The Contractor agrees to perform all tasks and provide deliverables as set forth in the Contract. The Department and the Customer will be entitled at all times, upon request, to be advised as to the status of work being done by the Contractor and of the details thereof.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!